

Patent Act (amdt.)(Bill C-22)—Minister of...—Cont.

Reprint, as amended, 17:51, agreed to, 17

Title, 17:50, carried, 17

References

Alternatives, Eastman report/status quo, etc., 9:16, 43, 53;
14:22-3; 15:33

See also Patent Act (amdt.)(Bill C-22)—References, Andre statement

Amending, 1:39-40; 3:11, 51, 65-7; 8:20, 45-6, 63; 13:44; 15:20, 35, 51-2

Andre consultations, provinces/groups, extent, 16:12-4

Information, tabling, 16:13

Andre statement/Eastman report comparing, 8:62, 65

Background, Harley committee, etc., 9:30

Benefits, 3:46-8, 51, 67; 6:28, 46; 14:9-10, 21

Cabinet and parliamentary review provision, 8:65; 10:9, 40; 11:28; 12:28; 13:16, 24; 14:9, 30, 45-6; 15:20, 33; 16:18, 25; 17:42-3

Competition Tribunal Act (Bill C-91)(1st Sess., 33rd Parl.), comparison, 8:22-3

Cost impact studies see Access to Information Act; Consumer and Corporate Affairs Department—Andre; National Health and Welfare Department—Minister

Drafting, significant changes made, 1:20, 34, 37, 39-41; 6:64; 15:87-8

Eastman, Harry, position/consultation, 8:23; 11:28, 71-2

Expediting, Committee study curtailing, 6:68; 16:17

Liberal government, former, intentions, Frith comments, 15:65

Monopoly situation, creating, 3:7; 6:57; 8:25, 59; 10:21; 14:33

Political considerations, Shamrock Summit promises, etc., 6:48, 52, 56-7; 14:25, 30; 16:78

Purpose, 1:11; 6:61, 72; 9:9

Regulations, Governor in Council enabling, 12:50-1; 15:52; 16:19, 24, 32

Regulatory powers, excessive, 6:10, 14

Sunset clause, Canadian Cancer Society proposal, 16:25

See also particular subjects

Patent Act (amdt.)(Bill C-22) Legislative Committee see Committee**Patent agents register see Drug patents—Applications****Patent and Trademark Institute see Witnesses****Patent attorneys**

Future demand, 8:57

Patent Co-operation Treaty, 1:11; 8:18

Governor in Council regulations enabling, 16:32-4

Ratification, effect, 8:27-8

Patent Office see Canadian Patent Office**Patented Medicine Prices Review Board see Drug Prices Review Board****Patenting Life Forms and Processes see Consumer and Corporate Affairs Department—Publication****Patents see Drug patents****Pellizzari, Rosanne (Ontario Medical Reform Group)**

Patent Act (amdt.)(Bill C-22), 9:4, 41-2, 46, 49-52

Petroleum Incentives Program see Scientific Research Tax Credit Program**Pharmacare programs see Drug plans—Manitoba; Drugs and pharmaceuticals—Provinces****Pharmaceutical Manufacturers Association of Canada, 17:32**

Andre meeting, Bill C-22, 3:61

Pharmaceutical Manufacturers Association of Canada—Cont.

Canadian ownership, 3:58

Lobbying pressure, 6:86; 11:6-7, 55

Erola, threats, *The Inside Dope* publishing, 11:55; 15:98

See also Canadian Cancer Society

Progressive Conservative Party, federal, long-standing association, 6:57

Research and development facilities, 3:28, 56

See also Witnesses

Pharmacies see Windsor, Ont.**Pharmacists**

Background, brain drain, etc., 15:39-40

Legislation, Bill C-22 affecting, 12:64; 15:31-2, 40

Physicians/researchers

Manitoba, Bill C-22 supporting, 15:97

See also Drugs and pharmaceuticals—Costs/prices

PIP see Petroleum Incentives Program**Pipeline drugs see Generic drugs—Compulsory licensing, Notice of compliance****Plant-breeder rights**

Patent protection lacking, 5:37-8; 16:64

Podiluk, Walter (Saskatchewan Government)

Patent Act (amdt.)(Bill C-22), 11:3, 18-9, 23-9, 31

Polanyi, Dr. John

References, 3:36; 6:27

Politeski, Gordon J. (Biomira)

Patent Act (amdt.)(Bill C-22), 8:4, 50-8

Political parties see New Democratic Party; Progressive Conservative Party**Polls**

Government use, 11:62

See also Angus Reid & Associates

Possible Costs and Savings to the Provinces of Bill C-22 see Drugs and pharmaceuticals—Provinces**Poverty**

Statistics, male/female life-spans, etc., 11:52-3

Powell, Mary (Canadian Council on Social Development)

Patent Act (amdt.)(Bill C-22), 6:3, 64-5, 69-71

Premarin see Ayerst Laboratories**Prescription Drug Cost Regulation Act**

Ontario, 1986, product selection stimulating, 6:75

Primak, G.J. (Canadian Chamber of Commerce)

Patent Act (amdt.)(Bill C-22), 8:3, 22-3, 27

Princeton, N.J. see Ayerst Laboratories**Procedure and Committee business**

Acting Chairman, taking Chair, 6:5

Agenda and procedure subcommittee

Establishing, M. (Killens), 1:8, agreed to, 4

Reports

First, M. (Kempling), 2:5-7, agreed to on recorded division, 3

Second, M. (Kempling), 3:5, agreed to, 3

Bills

Amendments, admissibility, Royal Recommendation infringing, 17:33